Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RESIST3D

Financiado

Cerrado

Targeting drug resistance in ovarian cancer through large scale drug response pr...

Targeting drug resistance in ovarian cancer through large scale drug response profiling in physiologically relevant cancer organoids Ovarian cancer is the fifth most deadly cancer type among women in Europe. Despite the fact that standard chemotherapy is usually effective in eliminating bulk tumour mass, thereby inducing remission, most patients diagnosed with... ver más

31/08/2022

UCPH

207K€

Presupuesto del proyecto: 207K€

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-08-31

MSCA-IF-2018: Individual Fellowships

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UCPH

207.31K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CISTAX The inverse resistance relationship between platinum and tax... 45K€ Cerrado

OvCaPreMed OvCa for Precision Medicine Personalized Ovarian Cancer Tre... 201K€ Cerrado

TrackingTumorStates Tracking and Targeting Tumor States at single cell resolutio... 3M€ Cerrado

CANPLAST Cancer cell plasticity on targeted therapy 2M€ Cerrado

MR O MICS Unravelling Tumour Biology In Ovarian Cancer With Precision... 1M€ Cerrado

CROC The natural K, Fe, and Cu isotopic response to Pt-based chem... 176K€ Cerrado

Duración del proyecto: 41 meses Fecha Inicio: 2019-03-18
Fecha Fin: 2022-08-31

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 207K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Ovarian cancer is the fifth most deadly cancer type among women in Europe. Despite the fact that standard chemotherapy is usually effective in eliminating bulk tumour mass, thereby inducing remission, most patients diagnosed with advanced ovarian cancer die from the disease, as relapsed lesions emerge from small subpopulations of surviving drug-resistant cells. Precision medicine aims to improve cancer care through tailoring individualized therapies based on genomic or functional profiling of human cancers. However, as these approaches are usually performed on bulk tumour cells, the small pre-existing drug-resistant cell subpopulations remain untargeted. In the RESIST3D project, I will utilize ovarian cancer organoids – a patient-derived, three-dimensional cell cultures – to search for new strategies to eradicate drug-resistant cancer cells. I will use two organoid models developed for the same patient – one model derived from tumour material taken before chemotherapeutic treatment and one from a post-treatment sample, typically enriched in drug-resistant cells. I will further enrich the organoids in quiescent, drug-resistant cells by maintaining them in physiologic-like culture medium. I will then apply the models for drug-response profiling in order to identify agents that eradicate pre-existing drug-resistant cells, which could be combined with standard chemotherapy. Finally, I will assess whether the selected combinations prevent relapses in patient-derived xenograft mouse models. RESIST3D sets a new direction in precision cancer medicine, as it focuses on targeting small pre-existing subpopulations of drug-resistant cells rather than bulk tumour mass. Through combining organoid model, paired samples for each patient and physiologic culture conditions, I expect to identify new ways to target drug-resistant ovarian cancer cells. Moreover, RESIST3D will provide me with new research expertise and a scientific network that will enhance my research career.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores